We are live on ! Find out more
BBA

Baker Bros. Advisors Portfolio holdings

AUM $17.4B
1-Year Est. Return 131.5%
This Fund
S&P 500
This Quarter Est. Return
-4.33%
1 Year Est. Return
+131.5%
3 Year Est. Return
+336.81%
5 Year Est. Return
+553.16%
10 Year Est. Return
+4,134.93%
AUM
$11.5B
AUM Growth
-$794M
Cap. Flow
+$217M
Cap. Flow %
1.89%
Top 10 Hldgs %
81.68%
Holding
128
New
8
Increased
22
Reduced
12
Closed
5

Top Buys

Rank Stock Value
1
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$146M
2
ABLX
Ablynx NV
ABLX
+$94M
3
PHXM
PHAXIAM Therapeutics S.A.. American Depositary Shares
PHXM
+$73M
4
RYTM icon
Rhythm Pharmaceuticals
RYTM
+$54.2M
5
ACAD icon
Acadia Pharmaceuticals
ACAD
+$45M

Top Sells

Rank Stock Value
1
AAAP
Advanced Accelerator Applications S.A.
AAAP
+$170M
2
AKAO
Achaogen Inc
AKAO
+$47.2M
3
NDRM
NeuroDerm Ltd. Ordinary Shares
NDRM
+$22.2M
4
EXEL icon
Exelixis
EXEL
+$15.3M
5
LOXO
Loxo Oncology, Inc
LOXO
+$8.85M

Sector Composition

Rank Sector Weight
1 Healthcare 93.21%
2 Technology 0.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
EXEL icon
26
Exelixis
EXEL
$14B
$45.8M 0.4%
1,506,499
-575,513
-28% -$15.3M
BLCM
27
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
$42.3M 0.37%
503,231
– –
ACGN
28
DELISTED
Aceragen Inc
ACGN
$38.6M 0.34%
134,810
+58,949
+78% +$16.8M
RXDX
29
DELISTED
Ignyta, Inc.
RXDX
$37M 0.32%
1,384,266
+85,067
+7% +$1.38M
BLUE
30
DELISTED
bluebird bio
BLUE
$35.6M 0.31%
15,440
-3,199
-17% -$6.49M
SGMO
31
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$34.7M 0.3%
2,113,376
– –
CERS icon
32
Cerus
CERS
$575M
$32.9M 0.29%
9,745,209
– –
HALO icon
33
Halozyme
HALO
$9.82B
$32M 0.28%
1,581,424
– –
ABEO icon
34
Abeona Therapeutics
ABEO
$342M
$31.5M 0.27%
79,375
+12,000
+18% +$4.96M
GWPH
35
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
$29.3M 0.25%
221,800
+146,800
+196% +$17.2M
CBAY
36
DELISTED
Cymabay Therapeutics
CBAY
$27.5M 0.24%
2,991,775
– –
AIMT
37
DELISTED
Aimmune Therapeutics
AIMT
$25.5M 0.22%
673,908
– –
LKFT
38
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.82B
$24.4M 0.21%
259,894
– –
CPRX
39
DELISTED
Catalyst Pharmaceutical
CPRX
$22.9M 0.2%
5,852,153
+750,000
+15% +$2.48M
MRUS
40
DELISTED
Merus
MRUS
$22.5M 0.2%
1,160,014
– –
NTLA icon
41
Intellia Therapeutics
NTLA
$1.5B
$22M 0.19%
1,145,453
+83,333
+8% +$1.92M
INSM icon
42
Insmed
INSM
$22.6B
$21.8M 0.19%
700,000
– –
XNCR icon
43
Xencor
XNCR
$1.45B
$19.1M 0.17%
872,072
– –
PGNX
44
DELISTED
Progenics Pharmaceuticals Inc
PGNX
$18.7M 0.16%
3,150,808
– –
ANAB icon
45
AnaptysBio
ANAB
$1.53B
$18.3M 0.16%
181,386
+70,000
+63% +$5.15M
AERI
46
DELISTED
Aerie Pharmaceuticals
AERI
$17.9M 0.16%
299,356
– –
IMGN
47
DELISTED
Immunogen Inc
IMGN
$16.4M 0.14%
2,563,489
-125,000
-5% -$771K
MYOK
48
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$15M 0.13%
355,264
– –
FOMX
49
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
$14.8M 0.13%
2,466,702
– –
ASMB icon
50
Assembly Biosciences
ASMB
$494M
$14.6M 0.13%
26,894
+6,061
+29% +$2.74M
1
2
3 4 5

Similar funds

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $17.1B AUM 70.99% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
ASRS
Arizona State Retirement System Phoenix, Arizona $17.1B AUM 30.52% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
VMPIC
Varma Mutual Pension Insurance Co Helsinki, Finland $17B AUM 24.09% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
BCIM
British Columbia Investment Management Victoria, British Columbia, Canada $17B AUM 31.69% 1-Year Est. Return

Baker Bros. Advisors's Q4 2017 Portfolio in Review

As of Q4 2017, Baker Bros. Advisors held 128 positions worth $11.5B, down 6.4% from $12.3B the previous quarter. Its ten largest holdings account for 82% of the portfolio.

Baker Bros. Advisors's Q4 2017 filing shows 8 new, 22 increased, 12 reduced and 5 closed positions. Its largest new stake was Ablynx NV: 4,161,118 shares worth $104M. The largest sale was Advanced Accelerator Applications S.A., an estimated $170M.

By sector, the portfolio is most concentrated in Healthcare at 93% of assets, up from 93% a quarter earlier, followed by Technology.

  • Baker Bros. Advisors's largest Q4 2017 buy was Ablynx NV: 4,161,118 shares worth $104M.
  • Baker Bros. Advisors added most to BioMarin Pharmaceuticals in Q4 2017, an estimated $146M increase.
  • Baker Bros. Advisors's biggest Q4 2017 reduction was Advanced Accelerator Applications S.A., cutting an estimated $170M.
  • Baker Bros. Advisors fully exited NeuroDerm Ltd. Ordinary Shares in Q4 2017, selling an estimated $22.2M.
  • Baker Bros. Advisors's ten largest holdings make up 82% of its $11.5B portfolio in Q4 2017.
  • Baker Bros. Advisors opened 8 new positions and closed 5 in Q4 2017.
  • Baker Bros. Advisors's portfolio value fell 6.4% quarter-over-quarter to $11.5B.

Based on Baker Bros. Advisors's 13F filing for Q4 2017, filed 14 Feb 2018.